FierceBiotech: Meissa's Early Clinical Data on COVID-19 Vaccine Supports Transmission Blocking Role

This data provides support for Meissa's intranasal COVID-19 vaccine in breaking transmission chains.


From FierceBiotech:


Meissa Vaccines has presented early clinical data on its nasal COVID-19 vaccine, revealing the highest dose of the recombinant live attenuated candidate triggered similar nasal antibody levels to natural immunity.


Advocates of nasal COVID-19 vaccines see the delivery method as more than just a way to persuade needle-phobic people to get vaccinated. The broader case for nasal vaccines centers on the levels of antibodies in the upper airways where SARS-CoV-2 infections take root. Injected vaccines are good at providing systemic immunity but have less effect on the nose, potentially increasing the chances that vaccinated individuals will contract and pass on the virus, albeit without falling severely ill.


To read the full article, click here.